The Institute of Biomedical and Pharmaceutical Sciences at Guangdong University of Technology in Guangzhou – China, has successfully installed a VECTor5 Hybrid OI/CT system from MILabs.
This unique in vivo small animal imaging system combines three optical molecular imaging techniques – bioluminescence, fluorescence and Cherenkov luminescence – with ultra-high-resolution CT anatomical imaging. While each individual optical imaging modality offers industry-leading performance thanks to the use of a deep-cooled camera, users gain most benefits from the fusion of functional optical information with detailed anatomical CT data. MILabs’ VECTor is the first and only optical imaging platform that comes with 3D/4D diagnostic CT imaging capabilities, allowing users to extract more data from fewer animals.
Guangdong University of Technology (GDUT) is one of Guangdong’s leading universities. It is a comprehensive research-oriented university, offering a wide range of courses in engineering, science, technology, management, liberal arts and law. GDUT was formerly known as Guangdong Institute of Technology, which was found in 1952. Approved by the State Education Commission in June 1995, it merged Guangdong Institute of Mechanical Engineering and the east campus of South China Institute of Architecture.
According to Dr. Song, investigator of Institute of Biomedical and Pharmaceutical Sciences at GDUT:
We are excited about the installation of MILabs Hybrid/OI/CT system since it offers research capabilities beyond those of other optical imaging systems by linking optical function imaging to high-quality CT imaging, even in complex biological systems such as small mouse models of human diseases. This multi-modality system will promote our development of a high-level university and I’m looking forward to seeing our team members reach more and more scientific achievements.
Prof. Frederik Beekman, MILabs CEO adds:
We are looking forward to collaborating with GDUT’s Institute of Biomedical and Pharmaceutical Sciences. Their dedication of large resources to the research and development of innovative new drugs and medical products is synergistic with our own strategy of supplying the most advanced molecular imaging systems to the global scientific community.